Literature DB >> 16042721

New perioperative management reduces bleeding in radical retropubic prostatectomy.

Martin Schostak1, Klaudia Matischak, Markus Müller, Michel Schäfer, Mark Schrader, Frank Christoph, Kurt Miller.   

Abstract

OBJECTIVE: To describe the effect of modifications to radical retropubic prostatectomy (RRP, known to be associated with severe bleeding) on blood loss in a retrospective analysis comparing RRPs by one experienced surgeon before and after the changes. PATIENTS AND METHODS: The new method comprised reducing the intravenously applied volume, using a peridural catheter and maintaining a 25-30 degrees Trendelenburg position. The difference in haemoglobin before and after RRP was analysed before the changes (group 1) and after (group 2). If transfusions were required the haemoglobin value was corrected, whereby 1 mL of erythrocyte concentrate increased the patient's haemoglobin by 0.03 g/L.
RESULTS: Assessment was possible in 201 of 234 patients, 110 from group 1 and 91 from group 2. The mean transfusion-corrected difference in haemoglobin was 53 g/L in group 1 (20% transfusion rate) and 35.2 g/L in group 2 (1.09% transfusion rate; P > 0.001). The median intravenous volume applied was 5.96 L in group 1 and 3.49 L in group 2 (P < 0.001). The complication rate did not differ between the groups.
CONCLUSION: This new method minimizes the intraoperative blood loss during RRP; transfusions are only necessary in rare cases and the complication rate remained unaltered.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16042721     DOI: 10.1111/j.1464-410X.2005.05622.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  1 in total

Review 1.  [Fast-track surgery in radical retropubic prostatectomy. First experiences with a comprehensive program to enhance postoperative convalescence].

Authors:  H Heinzer; R Heuer; O V Nordenflycht; C Eichelberg; P Friederich; A E Goetz; H Huland
Journal:  Urologe A       Date:  2005-11       Impact factor: 0.639

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.